|
Marijuana Abuse
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because the psychotropic effects and abuse liability of cannabis prevent its therapeutic application in depression and anxiety states, we decided to investigate the effects of the combination of ineffective doses of cannabinoid CB1 receptor agonist arachidonylcyclopropylamide (ACPA) and β-carbolines on anxiety- and depression-related behaviors in male NMRI mice.
|
30797851 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Synthetic cannabinoids are, typically, full agonists at the cannabinoid CB1 receptor, and therefore considerably more potent than natural cannabis and may have correspondingly more serious psychological effects.
|
30789300 |
2019 |
|
Marijuana Abuse
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These studies demonstrate that pathological and behavioral phenotypes associated with FASD are induced by exposure to CB1R agonists and suggest that combined exposure to lower levels of alcohol and marijuana may be capable of inducing FASD-like morphological and behavioral impairments.
|
30648819 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data implicate NAcore CB1R as critical regulators of metaplasticity induced by cannabis self-administration and the cues predicting cannabis availability.
|
31733097 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Choline transported into the amniotic fluid from the mother activates α7-nicotinic acetylcholine receptors on fetal cerebro-cortical inhibitory neurons, whose development is impeded by cannabis blockade of their cannabinoid-1(CB1) receptors.
|
31364525 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cannabinoids and their principle psychoactive target, the cannabinoid type 1 receptor (CB1R), impact a number of alcohol-related properties, and although alcohol and cannabis are often co-used, particularly in adolescence, few animal models of this phenomenon exist.
|
31524960 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
The most well established finding is the down-regulation of cannabinoid CB1 receptors (CB1R) after chronic and recent cannabis exposure, but it remains uncertain whether this effect is present in cannabis users with schizophrenia.
|
30635160 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Marijuana, a psychoactive drug that activates cannabinoid-1 (CB1) receptors in the brain, is the most prevalently abused illicit drug among American adolescents and young adults.
|
31120283 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant.
|
30077950 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, it is unclear which constituent in cannabis is responsible for these effects, or whether these are cannabinoid receptor 1 (CB1R) mediated.
|
29604295 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cannabinoids are the active ingredients of marijuana, which interact with cannabinoid receptors such as CNR1 and CNR2 to activate cellular signaling pathways.
|
29884300 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken collectively, the atypical pharmacodynamic properties of AB-PINACA at CB1Rs relative to Δ<sup>9</sup>-THC (e.g., higher potency/efficacy and greater production of desensitization), coupled with an unusual metabolic profile (e.g., production of metabolically stable active phase I metabolites) may contribute to the pronounced adverse effects observed with abuse of this SCB compared to marijuana.
|
30319418 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
The cannabinoid-1 receptor (CB1R) agonist Δ9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, adversely effects working memory performance in humans.
|
28641496 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, delta-9-tetrahydrocannabinol (THC), the primary psychoactive component in cannabis, is associated with acute and neurodevelopmental propsychotic side effects through its interaction with central cannabinoid type 1 receptors (CB1Rs).
|
29063964 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
The cannabinoid receptor 1 (CB<sub>1</sub>) is the principal target of the psychoactive constituent of marijuana, the partial agonist Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC).
|
28678776 |
2017 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consumption of cannabinoid receptor-1 (CB-1) agonist such as cannabis is widely taken in 3,4- methylenedioxymethamphetamine (MDMA) or ecstasy users; it has been hypothesized that co-consumption of CB-1 agonist might protect neurons against MDMA toxicity.
|
28167133 |
2017 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Yet, very few studies have been designed to directly assess the role of CB1 receptors in mediating the effects of cannabis on human brain function.
|
28414051 |
2017 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vitro studies suggest that synthetic cannabinoids in these preparations are potent agonists at central cannabinoid CB1 receptors (CB1Rs), but few investigations have delineated their cellular effects, particularly in comparison with the psychoactive component of marijuana, Δ<sup>9</sup> -tetrahydrocannabinol (Δ<sup>9</sup> -THC).
|
26732435 |
2017 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that the acute effects of cannabis on anxiety in males are mediated by the modulation of amygdalar function by delta-9-THC and the extent of these effects are related to local availability of CB1 receptors.
|
29101333 |
2017 |
|
Marijuana Abuse
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that activation of CB1Rs in VgluT2-expressing glutamate neurons produces aversive effects that might explain why cannabinoid is not rewarding in rodents and might also account for individual differences in the hedonic effects of cannabis in humans.
|
28951549 |
2017 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CNR1 haplotypes were formed from four CNR1 SNPs (rs806368, rs1049353, rs2023239, and rs6454674) and tested with level of cannabis exposure to assess their interactive effects on the lingual gyrus, cingulum (right and left) and rolandic operculum, regions showing cannabis exposure effects in the SPM8 analyses.
|
27500453 |
2016 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, DLPFC activity in the cluster associated with the CNR1 by PTGS2 interaction was negatively correlated with behavioral efficiency and positively correlated with frequency of cannabis use in cannabis users.
|
27261878 |
2016 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cannabinoid receptor 1 (CNR1) gene polymorphisms have been associated with central and peripheral effects of cannabis and schizophrenia pathophysiology.
|
26071625 |
2015 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Then, we studied whether functional variation in CNR1 and cannabis exposure interact in modulating prefrontal function and related behavior during working memory processing.
|
25139064 |
2015 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we assessed the influence of another cannabinoid-related gene, mitogen-activated protein kinase 14 (MAPK14), and potential MAPK14-CNR1 gene-gene interactions in conferring brain volume abnormalities among schizophrenia patients with marijuana abuse/dependence.
|
22850347 |
2013 |